NIGERIANS IN DIASPORA TO ESTABLISH A PHARMACEUTICAL COMPANY IN KADUNA STATE TO BE CALLED KADUNA MILLENIUM PHARMACEUTICAL LIMITED

Following  His Excellency Arc Namadi Sambo's meeting with some prominent Nigerians in Diaspora during the World Bank Spring Meeting in Washington DC, USA, a group from the Pharmaceutical Industries decided to come and establish a Pharmaceutical Company in Kaduna state based on a PPP arrangement. Arrangement has reached advanced state in the preparation for setting up the company

The benefits that will accrue from this project to Kaduna state include but not limited to:

1. The generation of over 500 new jobs, most of which would be high paying jobs, during the first three years of operation of the company.
   • 200 jobs (manufacturing and plant administration)
   • 300 jobs ( Medical representatives, distribution and  accounting etc)
2. Substantial savings to the state administered health-care program. It is conservatively estimated that the State government present drug program cost will be reduced by a minimum of 50%.
3. Revenue generation for the government and local economy in the form of additional tax base from both corporate taxes as well as individual taxes.
4. Most important, the provision of low cost, affordable and genuine generic drugs to our citizenry, particularly the elderly that consume lots of prescription drug and the poor.
5. Furthermore, it is anticipated that Millennium Pharmaceutical Limited will be listed as a public company, following an initial public offering (IPO), on the Nigerian Stock Exchange after 3 years of operation. Kaduna State Government as an investor in this Public-Private Partnership (PPP) will benefit immensely financially. The funds that would be raised through the IPO will be used to develop the permanent site of the company, increase company’s product portfolio offering and for company’s administrative and other expenses.
6. It is further anticipated that the proposed pharmaceutical manufacturing plant will meet US FDA standards and hence qualify to manufacture drugs for third world countries under the Canadian, US government, Bill and Melinda Gates Foundations and WHO programs for anti-malarials, HIV and other drugs.
7. The Quality Control Laboratory of Kaduna Millennium Pharmaceutical Limited will be able to tests, for a fee, products purchased by the State Government from vendors/suppliers to ensure that quality products are dispensed by government institutions to our citizenry and not fake adulterated drugs

OFF-SHORE PARTNERS [CANADIAN MILLENNIUM PHARMACEUTICAL LIMITED (CMPL)]

RESEARCH AND DEVELOPMEN

CMPL has made substantial investment in Research and Development (R&D) to develop 10 products for the Nigerian market. These include two anti-malarial drugs that are currently recommended by World Health Organization (WHO) for the treatment of malaria, and for which the WHO has earmarked 200 million dollars to purchase these drugs for free distribution to third world countries including Nigeria.

The antimalarial drugs are

• Dihydoartemisinin (40mg) + Piperaquine Phosphate (320mg)
• Artemeter (80mg) + Lumefantrine (480mg)

The other 8 drugs are:

• Amlodipine 5mg and 10mg
• Cefuroxime 250mg and 500mg
• Amoxicillin + Potassium Clavulanate (4:1), 500mg + 125 mg
• Levofloxacin 500 mg
• Raberprazole 20 mg
• Azithromycin tablets,250mg
• Diclofenac tablets,100mg
• Ofloxacin tablets,250mg